Two-Threshold Model for Psilocybin Response in TRD: Research Implications

New Model Sheds Light on Psilocybin Response Variability

A September 2026 preprint (OpenAlex W7211936605) introduces a two-threshold model to explain why patients with treatment-resistant depression (TRD) show markedly different responses to psilocybin-assisted therapy. The model, not yet peer-reviewed or cited, posits that individual variability in therapeutic outcomes can be attributed to two distinct neurobiological or psychological thresholds that must be crossed during treatment. This framework aims to address longstanding questions about why some TRD patients experience significant improvement while others do not.

Mechanism: The Two-Threshold Model Explained

The two-threshold model asserts that psilocybin’s therapeutic effects in TRD depend on surpassing two separate response thresholds: an initial neurobiological activation threshold and a subsequent psychological integration threshold. According to the preprint, the first threshold involves sufficient engagement of serotonergic pathways (notably the 5-HT2A receptor), which is necessary but not sufficient for therapeutic benefit. The second threshold relates to the patient’s capacity for psychological insight, emotional processing, or integration of the psychedelic experience—factors often influenced by prior trauma, cognitive rigidity, or support structures.

This model suggests that patients who do not cross both thresholds may experience limited or transient benefits, explaining the heterogeneous results seen in clinical trials. Importantly, the authors propose that future studies should stratify participants based on baseline neurobiological and psychological readiness, potentially using biomarkers or psychometric tools—a nuance often overlooked in current trial protocols.

Implications for Clinical Trials and Policy

If validated, the two-threshold model could significantly influence the design of future psilocybin trials for TRD. Clinical researchers may need to adopt more granular inclusion criteria, moving beyond broad diagnostic categories to incorporate neurobiological or psychological screening measures. This approach could improve signal detection in efficacy studies and reduce the risk of false negatives due to heterogeneous samples.

• Trial Design: Adaptive or stratified trial designs may become standard, with interim analyses to identify subgroups crossing either or both thresholds.
• Patient Selection: Screening for neurobiological markers (e.g., baseline 5-HT2A receptor density via PET imaging) or psychological readiness (e.g., resilience or openness scores) could enhance response rates and safety.
• Policy and Access: Regulators and payers may require evidence of threshold-crossing potential before approving or reimbursing psilocybin-assisted therapy for TRD, complicating broad access but potentially improving outcomes.

One non-obvious implication is that the model could help explain why some real-world clinics report lower efficacy than tightly controlled trials: patient populations outside research settings may be less likely to cross both thresholds due to differences in preparation, support, or comorbidities.

Risks, Unknowns, and Validation Needs

The two-threshold model remains hypothetical and faces several challenges. The preprint has not undergone peer review, and its proposed mechanisms require empirical validation in both laboratory and clinical settings. There is also a risk that over-reliance on biomarkers or psychometric screening could inadvertently exclude patients who might benefit from therapy, or reinforce health disparities if advanced imaging or assessments are not widely accessible.

Additionally, the model’s complexity could complicate regulatory approval pathways. Agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) may require robust evidence that threshold-based selection improves outcomes without introducing new risks. Failure to validate the model could delay or complicate ongoing phase 3 trials and real-world implementation.

Looking Ahead: Research and Practice in Transition

The two-threshold model marks a significant step toward precision psychiatry in psychedelic research, but its utility will depend on rigorous validation and practical feasibility. Researchers are likely to prioritize studies that identify reliable predictors of threshold crossing, while clinicians and policymakers must balance the promise of targeted therapy with the need for equitable access. The next two years will be critical, as ongoing and upcoming trials may incorporate stratification strategies inspired by this framework, setting new standards for the field.

How we research: Authored by Dr. Alex Kim, PhD (Neuroscience), reviewed by Dr. Jamie Patel, MD (Psychiatry) on 2026-09-10. Sources: original preprint, FDA guidance, and clinical trial registries.